Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients


23 Nov 2019


Poster display session


Tumour Site

Hepatobiliary Cancers


Noha El Baghdady


Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422


N.S.E.D. El Baghdady1, L. El Wakeel2, M.A. Ellithy3, N. Eltohamy4, S.M. Shaheen5, A.E.R. El Naggar6

Author affiliations

  • 1 Clinical Pharmacy, Modern University for Technology and Information- Faculty of Pharmacy, 1234 - Cairo/EG
  • 2 Clinical Pharmacy, Ain Shams University-Faculty of Pharmacy, 1234 - Cairo/EG
  • 3 Clinical Oncology, Ain Shams university Faculty of medicine, 11361 - Cairo/EG
  • 4 Medical Oncology, Electricity Hospital, 202 - Cairo/EG
  • 5 Clinical Pharmacy, Ain Shams University - Faculty of Pharmacy, cairo/EG
  • 6 Clinical Pharmacology, Cairo University- Faculty of Medicine, Giza/EG


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 191P


Hepatocellular carcinoma [HCC] is the third leading cause of death from cancer worldwide. In Egypt, HCC accounts for about 4.7% of chronic liver disease. To date, no controlled studies have evaluated the Sorafenib efficacy in comparison to no treatment in HCC patients whose etiology of HCV genotype 4 (The most prevalent hepatitis C virus genotype in Egypt).


A multicenter prospective controlled interventional study. 110 Patients were evaluated for overall survival [OS], Progression-free survival [PFS], safety and quality of life [QOL] using FACT Hepatobiliary Symptom Index [FHSI-8] questionnaire. NCT02971696.


Out of 110 patients enrolled, only 55 completed the trial; sorafenib [n = 35], no-treatment control group [n = 20]. The one year OS was 0.0% versus 75.5% [p = 0.008] in control and sorafenib respectively. Median PFS was 5 months versus 12 months in control group and sorafenib respectively [p = 0.008]. Sorafenib group HR for developing progression was 2.35; [95% [CI], 1.19 to 4.62; P = 0.014]. QOL scores [FHSI-8] was significantly different between the 2 groups [F = 4.455, p = 0.047]. Most observed side effects of sorafenib were; Diarrhea [n = 15] and hand-foot syndrome [n = 12].


Sorafenib treatment showed a better outcome OS, PFS and QOL as compared to no-treatment in Egyptian patients with advanced Hepatocellular Carcinoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.